Current hemophilia treatment involves frequent intravenous infusions of clotting factors, which is associated with variable hemostatic protection, a high treatment burden, and a risk of the ...

Knowledge of the determinants of antithrombin specificity and the size requirement for bridging thrombin has led to the development of synthetic heparin mimetics containing an antithrombin-binding ...

Thrombate III is the only antithrombin concentrate approved in both adult and pediatric patients for hereditary antithrombin deficiency. The Food and Drug Administration (FDA) has expanded the ...

The assay now can measure antithrombin (AT) activity levels for people treated with Qfitlia Qfitila will support people living with hemophilia A or B, with or without inhibitors, by helping to ...

We identified a novel mechanism of hereditary thrombosis associated with antithrombin resistance, with a substitution of arginine for leucine at position 596 (p.Arg596Leu) in the gene encoding ...

Fitusiran antithrombin-based dose regimen targeting 15%-35% of antithrombin activity demonstrated favorable safety profile in male participants aged ≥ 12 years with severe hemophilia A or B, with or ...

Dose and frequency should be adjusted based on antithrombin activity, using the Innovance Antithrombin companion diagnostic test. The Food and Drug Administration (FDA) has approved Qfitlia (fitusiran ...

Learn the correct pronunciation of the Antithrombin- Recombinant, understand it's uses, recommended dosages, its indications, how to take, when to take, when not to take, side effects, special ...

The Case: A previously healthy 24-year-old man presented to the emergency department with sudden onset of severe periumbilical and right costovertebral pain accompanied by nausea and vomiting. His ...

Antithrombin III (human) 500 IU; per vial; lyophilized pwd for IV infusion after reconstitution; preservative-free. Antithrombin, an alpha2-glycoprotein, is normally present in human plasma and is the ...